Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

University of Ottawa

$100,000.00

The role of NF-kappaB in aberrant mammary progenitor cell function and development of breast cancer in BRCA1/2 mutation-carriers

FY 2015-16

Summary
Individuals with a mutation of the BRCA2 breast cancer susceptibility gene have an average lifetime risk of breast cancer of approximately 40-60%. Currently, there is no targeted way to prevent BRCA1-mutation associated familial breast cancer. One way to approach this problem is to identify the causes of precancerous changes in the mammary gland. Activation of a family of proteins called NF-kappaB have a normal, hormonally-regulated role in the development and expansion of the mammary gland. However we have found that deficiency/mutations in BRCA1 or 2 result in enhanced and deregulated NF-kappaB activation (ie. active all the time). In BRCA1-deficiency this results in an abnormal population of unstable mammary cells. We have previously demonstrated that this population can be drastically reduced by inhibition of NF-kappaB. Approaches to prevention must target specific cell signals that are important for precancerous changes. In this proposal we will determine the role of NF-kappaB in the early events in the mammary gland cells that predispose to breast cancer when BRCA2 is deficient. We will also investigate novel gene expression that perpetuates the abnormal cell proliferation in the mammary gland of carriers of BRCA2 mutations. Finally, we will evaluate the effects of NF-kappaB inhibition on the development of mammary cancers in a model of BRCA2-deficient breast cancer in mice. The outcome of this proposal will be improved risk evaluation, new methods of prevention and targeted treatment for BRCA familial breast cancers.
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
333023
Name
Pratt Christine M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
The role of NF-kappaB in aberrant mammary progenitor cell function and development of breast cancer in BRCA1/2 mutation-carriers
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Brca1/Basal Cancer; Breast Cancer; Nf-Kappa B Transcription Factor; Stem / Progenitor Cells; Transgenic Mice
Abstract
Individuals with a mutation of the BRCA2 breast cancer susceptibility gene have an average lifetime risk of breast cancer of approximately 40-60%. Currently, there is no targeted way to prevent BRCA1-mutation associated familial breast cancer. One way to approach this problem is to identify the causes of precancerous changes in the mammary gland. Activation of a family of proteins called NF-kappaB have a normal, hormonally-regulated role in the development and expansion of the mammary gland. However we have found that deficiency/mutations in BRCA1 or 2 result in enhanced and deregulated NF-kappaB activation (ie. active all the time). In BRCA1-deficiency this results in an abnormal population of unstable mammary cells. We have previously demonstrated that this population can be drastically reduced by inhibition of NF-kappaB. Approaches to prevention must target specific cell signals that are important for precancerous changes. In this proposal we will determine the role of NF-kappaB in the early events in the mammary gland cells that predispose to breast cancer when BRCA2 is deficient. We will also investigate novel gene expression that perpetuates the abnormal cell proliferation in the mammary gland of carriers of BRCA2 mutations. Finally, we will evaluate the effects of NF-kappaB inhibition on the development of mammary cancers in a model of BRCA2-deficient breast cancer in mice. The outcome of this proposal will be improved risk evaluation, new methods of prevention and targeted treatment for BRCA familial breast cancers.
Competitiondate
201505
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pratt, Christine M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
University of Ottawa - $100,000 Grant (2015-16) | Canada Spends